EP Patent

EP1208231A2 — Means for detecting and treating pathologies linked to fgfr3

Assigned to Centre National de la Recherche Scientifique CNRS · Expires 2002-05-29 · 24y expired

What this patent protects

The invention relates to a method for detecting carcinomas in a biological sample, comprising identifying FGFR3 mutations.

USPTO Abstract

The invention relates to a method for detecting carcinomas in a biological sample, comprising identifying FGFR3 mutations.

Drugs covered by this patent

Patent Metadata

Patent number
EP1208231A2
Jurisdiction
EP
Classification
—
Expires
2002-05-29
Drug substance claim
No
Drug product claim
No
Assignee
Centre National de la Recherche Scientifique CNRS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.